Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
English version
Adhoc Press Release
Kuros Biosciences reports results for the first six months of 2022
German version
Adhoc Press Release
Annual General Meeting of Kuros Biosciences approves all resolutions
Adhoc Press Release
Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment
Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial